30.04.2018 Elanix Biotechnologies AG  DE000A0WMJQ4

DGAP-News: Elanix Biotechnologies Raises up to 2.5 Million EUR Through Standby Equity Distribution Agreement and Announces Preliminary Fiscal Year 2017 Results

DGAP-News: Elanix Biotechnologies AG / Key word(s): Financing/Preliminary Results Elanix Biotechnologies Raises up to 2.5 Million EUR Through Standby Equity Distribution Agreement and Announces Preliminary Fiscal Year 2017 Results 30.04.2018 / 21:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE Elanix Biotechnologies Raises up to 2.5 Million EUR Through Standby Equity Distribution Agreement Tissue Regeneration Specialist Enters SEDA Agreement with Yorkville Advisors and Announces Preliminary Fiscal Year 2017 Results Berlin, Germany, 30 April , 2018 -- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products for chronic and acute wound care and advanced skin care products for dermatological and gynaecological applications, has announced it has entered a Standby Equity Distribution Agreement (SEDA) with Yorkville Advisors Global. Under the terms of the agreement, Yorkville has committed to provide up to EUR 2.5 million in equity financing over a 24-month period. As a result of the agreement, the share capital of Elanix will increase over time when the SEDA is used. "This SEDA provides Elanix with the financial flexibility to deliver on several product development milestones as well as ramping up our sales and marketing activities," said Tomas J. Svoboda, CEO of Elanix Biotechnologies AG. "This additional equity funding will enable to us to build on the significant progress we have made with product development and positioning to date." In addition to announcing the SEDA, Elanix has also published its preliminary financial results for fiscal year 2017. Based on unaudited numbers, the company achieved revenues of EUR 328,148 for the fiscal year. The company's net loss after taxes for FY17 is EUR 3,830 million compared to net losses of EUR 1,891 million in 2016. Elanix intends to publish its fully audited 2017 financial results on June 30th 2018 and to hold its Annual Shareholders' Meeting End of August 2018. "Elanix is executing well towards our stated business plan," said Tomas Svoboda. "Our 2017 results reflect a year of investment and expansion. We have successfully brought our first product to EU market and we are now in a strong position to expand our product portfolio in both advanced skin care and wound care. At Elanix we are dedicated to using innovative cell technologies to advance patient wound care and accelerate healing processes." Elanix has already launched GYNrepair(R) cream, developed and marketed by the company's wholly-owned subsidiary Repair-A SA, which is designed for use on the genital external mucosa to soothe the feeling of discomfort, twinges and dryness. Later this year, Elanix plans to expand its range of advanced skin care products with the SKINrepair(R) dermatological cream, intended to be used for sensitive or weakened skin with a tendency to irregularities. In addition, Elanix's "FirstCover" bioactive skin dressing which offers accelerated healing for burns, trauma and plastic surgery, is expected to receive market authorization in EU and CH as a medical device and be commercially available in 2020. #### Elanix develops and commercializes tissue regeneration products for chronic and acute wound care as well as specialty cosmetics for dermatological and gynaecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells. Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com. Yorkville Advisors Global, LP is a globally active investment manager for specialized financing solutions for listed stock corporations. The Healthcare Division of Yorkville, headed by managing director Saad Gilani, invests in a wide range of life science enterprises in the USA and Europe, specializing in biotechnology, molecular diagnostics, surgical instruments and medical products. Contacts: Elanix Biotechnologies AG Magdalena Onyszkiewicz Tel: +41 78 667 36 50 [1]investor.relations@elanix-bt.com 1. mailto:investor.relations@elanix-bt.com Disclaimer / Forward-looking statements: This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. --------------------------------------------------------------------------- 30.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Elanix Biotechnologies AG Kurfürstendamm 32 10719 Berlin Germany ISIN: DE000A0WMJQ4 WKN: A0WMJQ Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf End of News DGAP News Service --------------------------------------------------------------------------- 681123 30.04.2018

Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,33 0,06 0,00 0,00
EBITDA1,2 0,00 0,00 -3,16 -2,32 -3,13 -3,65 0,00 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 -948,48 -6.083,33 0,00 0,00
EBIT1,4 0,00 0,00 -3,16 -2,32 -4,39 -3,67 0,00 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 -1.330,30 -6.116,67 0,00 0,00
Jahresüberschuss1 0,00 0,00 -2,79 -1,89 -3,83 -3,73 0,00 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 -1.160,61 -6.216,67 0,00 0,00
Cashflow1,7 0,00 0,00 -0,54 -0,82 -3,77 -2,55 0,00 0,00
Ergebnis je Aktie8 0,00 0,00 -0.54 -0,36 -0,58 -0,49 -0,17 -0,04
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

Elanix Biotechnologies
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0WMJQ 0,515 4,16
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 7,51 0,000 -1,12
-2,07 - 68,22 -1,209
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 24.08.2017
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2019 19.08.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
21,20% -2,61% -12,42% -68,69%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Elanix Biotechnologies AG  ISIN: DE000A0WMJQ4 können Sie bei DGAP abrufen

Biotechnologie , A0WMJQ , ELN , FWB:ELN